North Bud Farms Provides a Corporate Update
Momentum Public Relations
Press Release: October 16, 2018
North Bud Farms Inc.(CSE: NBUD) (“NORTHBUD” or the “Company”) is pleased to provide shareholders an update on our corporate activities.
Construction of Our Cannabis Production Facility in Low, Quebec:
NORTHBUD and its team have been hard at work finalizing some minor design changes to our proposed facility located on 95 acres of agricultural land in Low, Quebec. NORTHBUD has received a detailed timeline for construction from our builder, NGA Construction Inc., and is on schedule to have the facility completed and an evidence package submitted to Health Canada in Q1 2019. We are pleased to report the facility budget is on target.
All infrastructure implementation has been completed and physical facility construction will begin, October 17, 2018.
ACMPR Application:
As previously disclosed in our prospectus, NORTHBUD, through its wholly-owned subsidiary GrowPros MMP Inc. which was acquired from Tetra Bio-Pharma Inc. in February 2018, is pursuing a license under the Access to Cannabis for Medical Purposes Regulations (ACMPR). In this regard, NORTHBUD has engaged Cannabis Compliance Inc. to assist in the migration of the ACMPR application to the CLTS which goes into effect after the implementation of the Cannabis Act on October 17, 2018. NORTHBUD will be making amendments in order to take advantage of favourable changes that have been implemented under the Cannabis Act.
Key New Hires:
NORTHBUD is pleased to announce the hiring of Magda Farid who will serve as our head of Quality Assurance and Compliance. Ms. Farid previously served as head of quality assurance for HEXO Corp. (formerly known as The Hydropothecary Corporation), a licensed producer under the ACMPR, in addition to multiple roles as Quality Assurance Manager in the pharmaceutical industry with companies such as McKesson and Trillium Health Care Products Inc. Ms. Farid has a Bachelor of Science degree from the University of Ottawa with a double major in biochemistry and nutrition.
“NORTHBUD is very pleased to be able to bring on a quality assurance manager with experience in both the cannabis and pharmaceutical industries,” said Ryan Brown, CEO and Founder of North Bud Farms Inc. “This decision was made to bring in a new Quality Assurance Manager as we believe that a combination of experience in pharmaceutical and cannabis is critical for NORTHBUD to execute on its strategy to be a strategic supplier of Pharmaceutical and Food grade cannabis inputs. We are focused on strengthening our team to be prepared for Legalization 2.0 as well as exploring opportunities to accelerate our development and provide value to shareholders.”
About North Bud Farms Inc.
North Bud Farms Inc., through its wholly-owned subsidiary GrowPros MMP Inc. which was acquired in February 2018, is pursuing a license under the Access to Cannabis for Medical Purposes Regulations (ACMPR). North Bud Farms will be constructing a state-of-the-art purpose-built cannabis production facility located on 95 acres of Agricultural Land in Low, Quebec. North Bud Farms will be focused on Pharmaceutical and Food Grade cannabinoid production in preparation for the legalization of edibles and ingestible products scheduled for October 2019.
For more information visit: www.northbud.com
Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward- looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such risks and uncertainties include, among others, the risk factors included in North Bud Farms’ final long form prospectus dated August 21, 2018 which is available under the issuer’s SEDAR profile at www.sedar.com.
FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
investors@northbud.com
- Published in Business, Life Sciences, Medical Marijuana, News Home
Next Green Wave Holdings Inc. announces proposed acquisition of Loud Seeds – a High Times Hall of Fame inductee
Momentum Public Relations
Press Release: October 16, 2018
Next Green Wave Holdings Inc. (CSE : NGW) (“Next Green Wave” or the “Company“), is pleased to announce that it has entered into a letter of intent (“LOI“) whereby the Company intends to acquire 100% of Loud Seeds, LLC (“Loud Seeds”) along with the Loud Seeds brand and all of its related assets (the “Transaction“). As consideration for the Transaction, Next Green Wave intends to distribute $2,000,000 in common shares of the Company to the shareholders of Loud Seeds. Completion of the Transaction is subject to the satisfaction of a number of conditions, including completion of due diligence by the Company, obtaining all required regulatory approvals.
Michael Jennings, CEO and Director of NGW, is a principle in Loud Seeds. The Transaction is therefore a related party transaction and will be subject to the requirements of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions. The Transaction was approved by all the independent directors.
Loud Seeds is a multiple cannabis cup winner for its seeds and clones, has flourished as innovators in developing premium quality cannabis products to meet the dynamic consumer demands. The principles over the past 20 years have developed a vast collection of award-winning strains and has been inducted into the High Times Hall of Fame and the Top 40 Seed Banks of all time.
KEY HIGHLIGHTS
- Loud Seeds brings an extensive catalogue of cannabis genetics into Next Green Wave accelerating its nursery and cultivation ability
- Loud Seeds is a six-time High Times Cannabis Cup winner
- Loud Seeds has been inducted into the High Times Hall of Fame and listed in the Top 40 Seed Banks of all time
James Load (Principle / Founder) of Loud Seeds: “We are excited to bring our extensive portfolio into Next Green Wave, who’s vision and innovative nursery and cultivation style will see our Loud Seeds genetic library go to the next level. Next Green Wave’s cannabis platform is exceptional and their vision to be a dominate force in California and other jurisdictions is exciting for Loud Seeds.”
Leigh Hughes, Executive Chairman of Next Green Wave:“Being able to bring one of the best seed banks in the world into our nursery continues to differentiate Next Green Wave from other cultivators. “We are excited to join an award-winning genetics portfolio with world-class breeding skills as the construction of our first facility nears completion and begins cultivation.”
ABOUT LOUD SEEDS, LLC
Loud Seeds was founded by Kenneth James Koskiniemi (aka: James Loud) and Michael Jennings (aka: Mike Seeds) who have been growing and breeding premium cannabis for over 20 years with a focus on organic growing. Over that time, Loud Seeds has developed a vast collection of cannabis strains and worked with some of the finest cultivators in the United States and Europe on innovative growing techniques and breeding projects.
Loud Seeds has been inducted into the High Times Hall of Fame and listed in the Top 40 Seed Banks of all time. Being covered in the press by The Million Dollar Grow Room, America’s Next Pot Kings and the Top Ten Strains of the Year, the Loud Seeds brand is one of the more recognized seed brands in California. Loud Seeds have breeding methods that have been developed for over 20 years and are specialists in creating, launching and marketing new strains based on consumer demand. Loud Seeds has also built a strong distribution list in California along with relationships with many other well-known cultivators and breeding partners.
ABOUT NEXT GREEN WAVE HOLDINGS INC.
Headquartered in Western Canada, Next Green Wave is a vertically integrated premium medicinal and recreational cannabis company operating in California, one of the world’s largest cannabis markets. Led by award-winning cannabis industry veteran Michael Jennings and an industry innovator specializing in premium cannabis products. The Company has plans to build four facilities centrally located on 15.5 acres of land in Coalinga, California allowing for state-wide reach across the lucrative California market.
For information on Next Green Wave please visit www.nextgreenwave.com/investors. For copies of news releases and all company materials please refer to SEDAR (www.sedar.com). For all investor relations information, please refer to www.nextgreenwave.com/investors or contact IR@nextgreenwave.com or +1 778-589-5054.
- Published in Business, Life Sciences, Medical Marijuana, News Home
Tetra Bio-Pharma Names Dr. Guy Chamberland as Chief Executive Officer and Chief Scientific Officer
Momentum Public Relations
Press Release: October 15, 2018
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced the permanent appointment of Guy Chamberland, Ph.D., as CEO and CSO having most recently held the position of CEO in an interim capacity. Dr. Chamberland has more than 23 years’ experience in the development of new drugs in the North American pharmaceutical industry. He worked for more than 10 years as an executive with several biopharmaceutical companies and was a member of the investment committee of a venture capital fund for 7 years. Since joining Tetra Bio-Pharma in June 2016, Dr. Chamberland and his team have accomplished numerous milestones. These include having:
- Built a solid pipeline of five cannabinoid-based therapeutics using a variety of delivery mechanisms focused on a number of different disease indications many representing billion dollar markets;
- Developed an innovative regulatory strategy for each of these products to maximize approval success – thereby rapidly building shareholder value;
- Taking Tetra’s lead product PPP001 from concept to Phase 3 in less than two years and at 20 percent of the cost of a typical bio-pharma company;
- Taken the first smokable product into a Phase I and Phase III clinical trial;
- Structured company activities in three distinct commercial divisions: bio-pharma, natural health and veterinary medicine;
- Negotiated a major supply agreement with a well-established player in the natural health products market; and
- Increased the company’s share price more than 50% since assuming the role of interim CEO.
“We are extremely pleased with the progress that Guy has made since joining the company in 2016 and equally impressed with his accomplishments since being named interim CEO,” stated Tetra Bio-Pharma’s Chairman of the Board, Bill Cheliak. “It is for these reasons that the Board unanimously voted to permanently appoint Guy to the position of CEO, along with his role as Chief Scientific Officer. We look forward to seeing Guy and his team build on the tremendous momentum they have generated thus far and continue to increase shareholder value.”
“I am greatly honored by this nomination as well as by the confidence that the Board of Directors has shown in me,” said Dr. Chamberland. “As the CEO of Tetra Bio-Pharma I am excited and deeply committed to lead our team through the next stages of development. We are confident that our innovative pipeline of cannabis and cannabinoid products will play an important role in improving the lives of patients suffering from a range of chronic and acute pain conditions and have a significant impact in opioid sparing and/or replacement. It is evident that the pharmaceutical pathway that we are championing in order to establish the scientific evidence that regulators, the medical community and payers in Canada, the United States and Europe require in order to approve cannabis-based products is becoming better understood and increasingly welcomed. Our robust activity in the natural health sector further demonstrates our capacity for innovation.”
About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
- Published in Business, Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
MedX Health closes first tranche of placement
Momentum Public Relations
Press Release: October 11, 2018
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announces that, pursuant to a non-brokered Private Placement Offering (the “Placement Offering”), it has completed an initial Closing of 2,106,250 Units, to raise $337,000 from accredited investors. The Company is planning to raise up to $2.5 million by issuance of up to 15,625,000 Units from the Placement Offering. Each Unit, priced at $0.16, comprises one fully paid common share and one share purchase warrant; each warrant entitles the holder to purchase one additional share at a price of $0.35 during the period up to three years from the closing date of the placement. The securities issued as a result of the Placement Offering will be restricted from trading for four months following each Closing. The Placement Offering is still open to subscribers, and further subscriptions may be accepted for further Closings. This Closing, and any further Closing of the Placement Offering, is subject to all relevant regulatory and other consents and approvals, including acceptance by the TSX Venture Exchange.
Following this Closing, MedX has 133,916,401 common shares issued and outstanding.
About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.
This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company’s limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company’s projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181011005958/en/
Contacts:
MedX Health Corp
Scott Spearn, 905-670-4428 ext 229
President and CEO
or
Media Relations
Deborah Thompson, 416-918-9551
dthompson@medxhealth.com
- Published in Business, Life Sciences, MedX Health Corp., News Home, Technology
Tetra Bio-Pharma’s PPP002 on Track After Type C Meeting with FDA
Momentum Public Relations
Press Release: October 11, 2018
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced it received the response letter for a Type C meeting with the United States Food and Drug Administration (FDA) for PPP002, its dronabinol AdVersa™ mucoadhesive product. The meeting was held to confirm that the proposed chemistry and manufacturing and non-clinical development plan for PPP002 for the 505(b)(2) is acceptable.
The FDA established that Tetra Bio-Pharma’s proposed bridging strategy fulfilled all the requirements of the 505(b)(2) regulatory pathway for the product PPP002. The FDA also provided feedback on the chemistry and manufacturing aspects of the drug development plan. The FDA further confirmed that the product control strategy, ensuring the identity, potency, purity and quality of the PPP002 buccal tablets was acceptable thereby determining that Tetra Bio-Pharma’s plan is on track for drug approval.
“We have now completed our meetings with the U.S. FDA and Tetra is well on its way to finalizing the development plan to bring PPP002 to market,” said Guy Chamberland, M.Sc., Ph.D., Interim Chief Executive Officer and CSO of Tetra Bio-Pharma. “With both the Type B and C meetings now behind us, we are able to move forward with executing the clinical program for PPP002 and subsequently submit the New Drug Application to commercialize PPP002.”
Tetra, along with its partner IntelGenx Corp, is developing this product in the United States under the accelerated 505(b)(2) pathway for the indication of chemotherapy-induced nausea and vomiting, and anorexia and weight loss in people with AIDS. These are the same indications that have already been approved for Marinol®. The 505(b)(2) speciality Contract Research Organization, Camargo, is guiding the regulatory submissions to the FDA. Tetra is also developing PPP002 in Canada as an adjunct therapy for opioid reduction in patients with chronic pain.
According to the International Agency for Research on Cancer, the global chemotherapy-induced nausea and vomiting (CINV) market will reach a valuation of US $1.88 billion by 2020, an increase from its 2013 valuation of US$1.28 billion. Based on the expected improved safety profile of delayed release dronabinol, Tetra expects that AdVersa™ can gain significant market share within three years of its launch in the USA.
About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
- Published in Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
CROP Hemp-CBD Farm Enters Toll Processing Deal to Produce CBD Isolate as it Readies for Harvest
Momentum Public Relations
Press Release: October 10, 2018
CROP INFRASTRUCTURE CORP. (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR)announced today that its tenant has signed a toll processing deal whereby it will provide its dried hemp-CBD biomass to a processor who will then provide 50% of the finished product as ISO certified CBD isolate to CROP’s tenanted farm. The CBD isolate will be sold under the company’s brands Hempire, Tiff CBD, infused in to the company’s CannaDrink and sold under white label.
CROP’s tenant, at its Nye County hemp-CBD farm in Nevada, has already begun equipment readiness preparations as the harvest is imminent.
CROP will also be working with the toll processor to enter into further agreements to develop its own ISO extraction facility for its production capacity which is now expanded to over 1,800 acres for 2019. The processor has consulted with numerous Canadian ACMPR and US licensed cannabis cultivators and processors to develop GMP and ISO conforming extraction facilities.
According to cannabis industry analysts, The Brightfield Group, it is estimated the hemp CBD market alone could hit $22-billion by 2022.
CROP CEO, Michael Yorke, stated: “Being in a position to have CBD isolate from the 2018 harvest will enable the company to begin infusing products like the CannaDrink beverage line and begin developing relationships with bulk buyers in preparation for 2019. Even with a toll cost, upgrading CBD biomass to isolate should significantly increase the value of our tenant harvest. This new strategic-alliance opens up additional mutually beneficial opportunities, specifically those in developing our own extraction facilities, both in the US and Europe, which will be necessary to maximize the potential of our portfolio’s ongoing hemp-CBD and Cannabis-THC production.”
About CROP
CROP has a portfolio of cannabis projects including cultivation properties in California, two in Washington State, two in Nevada consisting of 2,800 acres, 3 dispensary applications, with international focuses in Jamaica and 2 farms in Italy. CROP has developed a portfolio of assets including CannaDrink and a portfolio of 16 Cannabis brands. with US and Italian distribution rights to over 55 topical products.
Company Contact
Michael Yorke – CEO & Director
E-mail: info@cropcorp.com
Website: www.cropcorp.com
Phone: (1) 604-484-4206
- Published in Business, CROP Infrastructure, Life Sciences, Medical Marijuana, News Home
Tetra Bio-Pharma Moves PPP001 Closer to Commercial Manufacturing with the Issuance of a Drug Establishment License to Ford’s Pharmacy
Momentum Public Relations
Press Release: October 3, 2018
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), in partnership with Ford’s Family Pharmacy and Wellness Center, have developed and implemented a pharmaceutical quality system for Canada’s first botanical-based prescription drug PPP001. The Good Manufacturing Practices, Regulatory Operations and Regions Branch, Health Canada completed the inspection of Ford’s manufacturing facility. A Drug Establishment License (DEL) was granted after having inspected and assessed the facility as being in compliance with the requirements of Divisions 2 to 4 of the Food and Drug Regulations thereby allowing Ford’s to conduct the fabrication, packaging and labeling of PPP001.
Dr. Guy Chamberland, M.Sc., Ph.D., Interim CEO and CSO of Tetra Bio-Pharma stated, “This is a significant accomplishment for Tetra and Ford’s. The manufacturing of a botanical drug is a complex operation and we have demonstrated to Health Canada that we are able to manufacture PPP001 in compliance with the requirements for a prescription drug. The DEL was required not just to manufacture the commercial lots but simply to enable Tetra to apply for approval and obtain the Drug Identification Number (DIN). Tetra is now in an excellent position to focus its activities on scale-up to ensure that we can supply the market demand for a first cannabis botanical drug. The DEL, a recognition of the pharmaceutical GMP quality process by Health Canada, was a critical milestone for Tetra to achieve thereby allowing the corporation to accelerate its plans to register cannabis drugs around the world including Europe and the USA.”
Dr. Peter Ford, CEO of Ford’s Family Pharmacy and Wellness Centre stated, “This has been a true team effort between Tetra and Ford’s and will potentially represent the very first smokable dosage form in Canada and beyond. We are both very much committed to the DIN application.”
Ofer Yifrach-Stav, Tetra Bio-Pharma Vice President, Pharmaceutical Compliance and Quality, said, “Tetra is proud to present a significant milestone in the development of PPP001, a prescription drug that contains a botanical ingredient, manufactured under the stringent requirements and regulations of Health Canada. The GMP inspection addressed a wide range of production activities, and the results demonstrate our consistent adherence to establish procedures at every step of the production process, as well as our ability to provide a high-quality, clean, safe and reliable product. We are excited to take the next steps in the development of cannabis botanical drugs with the potential of making them widely available to the public.”
About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
About Ford’s Family Pharmacy and Wellness Centre
Since 1997, Ford’s Family Pharmacy & Wellness Centre has helped clients improve and prolong their health, wellness and vitality by providing personalized compounding and wellness solutions. Our team, which currently consists of four pharmacists: Peter Ford, Bryan Sinclair, Candy Aguinaga, and Taylor White, 14 pharmacy technicians/assistants and two registered nurses, is attentive, compassionate, courteous and responsive. We pride ourselves on providing innovative solutions to complex medical problems, and work with Canadian healthcare providers (including physicians, veterinarians and dentists) to create well-rounded, comprehensive natural and compounding treatment plans. Our consultative approach, state-of-the-art technology and unique “Functional Medicine” position means we will work with you one-on-one to understand the root cause of your pain or other health issues and apply all our resources to developing the treatment that is right for you.
For more information visit: www.fordrx.com
Source: Tetra Bio-Pharma
- Published in Business, Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma